Conformational characterization of the mammalian‑expressed SARS‑CoV‑2 recombinant receptor binding domain, a COVID‑19 vaccine
Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines
In‑solution buffer‑free digestion allows full‑sequence coverage and complete characterization of post‑translational modifications of the receptor‑binding domain of SARS‑CoV‑2 in a single ESI–MS spectrum
A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies
SARS-CoV‑2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein


Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combinationwith SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
Efficacy and safety of a protein-based SARS-CoV-2 vaccine (Soberana 02 and Soberana Plus), a randomized clinical trial
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Progresión de la COVID-19 en trabajadores de una institución de salud cubana, vacunados con el esquema heterólogo de SOBERANA
Estudio de intervención con SOBERANA® en los trabajadores del Centro Nacional de Biopreparados
Real-world effectiveness of the SOBERANA02 and SOBERANA-Plus vaccine combination in children 2 to 11 years of age during the SARS CoV-2 Omicron wave in Cuba: a regression discontinuity study
PastoCovac and PastoCovac Plus as protein subunit COVID‑19 vaccines led to great humoral immune responses in BBIP‑CorV immunized individuals
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
SOBERANA®Plus: safe and efficient reinforcement of preexisting natural immunity against SARS-CoV-2
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
Farmacovigilancia intensiva de vacunas SOBERANA®02 y Soberana®Plus en población pediátrica en el Centro de Inmunología Molecular
Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children